Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Nuo Therapeutics stock

AURX
US67059V2097
A2AP5P

Price

1.22
Today +/-
-0.01
Today %
-0.82 %

Nuo Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Nuo Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Nuo Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Nuo Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Nuo Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Nuo Therapeutics Stock Price History

DateNuo Therapeutics Price
2/27/20251.22 undefined
2/26/20251.23 undefined
2/20/20251.13 undefined
2/19/20251.10 undefined
2/18/20251.11 undefined
2/17/20251.19 undefined
2/13/20251.19 undefined
2/12/20251.33 undefined
2/10/20251.48 undefined
2/9/20251.48 undefined
2/6/20251.52 undefined
2/4/20251.41 undefined
2/3/20251.50 undefined
2/2/20251.30 undefined

Nuo Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Nuo Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Nuo Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Nuo Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Nuo Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Nuo Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Nuo Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Nuo Therapeutics’s growth potential.

Nuo Therapeutics Revenue, EBIT and net profit per share

DateNuo Therapeutics RevenueNuo Therapeutics EBITNuo Therapeutics Net Income
2023608,530 undefined-3.17 M undefined-3.17 M undefined
2022110,000 undefined-3.32 M undefined-3.17 M undefined
20210 undefined-90,000 undefined-890,000 undefined
20200 undefined-380,000 undefined7.71 M undefined
2019150,000 undefined-970,000 undefined-1.19 M undefined
20181.37 M undefined-1.5 M undefined-1.54 M undefined
2017720,000 undefined-6.23 M undefined-14.98 M undefined
20162.2 M undefined-8.31 M undefined22.48 M undefined
201511.51 M undefined-14.27 M undefined-52.81 M undefined
20147.76 M undefined-18.71 M undefined-18.88 M undefined
201311.57 M undefined-18.1 M undefined-20.25 M undefined
201210.56 M undefined-12.37 M undefined-19.81 M undefined
20117.25 M undefined-3.52 M undefined-3.86 M undefined
20103.91 M undefined-5.4 M undefined-9.04 M undefined
20092.07 M undefined-3.45 M undefined-3.27 M undefined
20082.09 M undefined-4.35 M undefined-7.68 M undefined
20071.94 M undefined-5.35 M undefined-5.07 M undefined
20061.95 M undefined-3.91 M undefined-2.04 M undefined
20051.52 M undefined-7.35 M undefined-6.49 M undefined
20041.15 M undefined-8.24 M undefined-11.31 M undefined

Nuo Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
1999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
0000111112237101171120100000
---------100.00-50.00133.3342.8610.00-36.3657.14-81.82-------
----100.00100.00100.00100.00100.0050.0050.0066.6757.1460.0027.2714.2927.2750.00-100.00-----
0000000011124630300100000
-6-33-215-4-11-6-2-5-7-3-9-3-19-20-18-5222-14-1-170-3-3
-450.00-36.36-123.81-180.00175.00-45.45-66.67150.0040.00-57.14200.00-66.67533.335.26-10.00188.89-142.31-163.64-92.86--800.00---
1.332.0511.7611.7611.8418.0924.4327.4729.8232.5235.1238.6750.6781.86103.62120.52125.959.9514.6523.2823.7227.3130.34042.08
-------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Nuo Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Nuo Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (k)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (k)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (k)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
19981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                   
00.122.120.180.950.813.283.124.665.144.032.110.642.252.623.2915.950.922.620.690.640.020.161.412.050.93
00.040.230000.110.110.030.020.020.051.180.871.092.430.581.010.290.110.020000.090.25
0000.01000.210.340.950.720.470.130.030.610.641.51.31000000000
000.0200000000.040.030.630.551.171.110.560.250.070.040.030000.240.21
00.030.110.290.260.190.270.220.160.240.160.21.020.890.921.633.490.850.380.340.180.2600.050.260.17
00.192.480.481.2113.873.795.86.124.722.523.55.176.449.9621.893.033.361.180.870.280.161.462.641.56
00.070.5100.310.240.20.080.010.020.090.081.330.982.440.920.931.120.490.220.110000.410.31
00000000000000000000000000
0000000305701900000000000000000
0000.644.364.232.081.961.821.67003.182.9234.1433.7728.752.517.840000000
0000002.022.022.022.02000.710.711.131.131.1302.080000000
00.020.880.060.040.040.0200000.040.190.320.180.483.550.40.280.02000000
00.091.390.74.714.514.324.094.423.90.090.125.414.9337.8936.334.364.0310.690.240.110000.410.31
00.283.871.185.925.518.197.8810.2210.024.812.648.9110.144.3346.2656.257.0614.051.420.980.280.161.463.051.88
                                                   
00000000000001050094091091000000004.42
09.9544.8851.266.9412.3824.8430.9234.8540.0342.2241.8347.5954.46108.49117.1125.17125.9618.1821.1622.1322.22324.3828.9530.97
-0.02-6.22-39.56-60.83-2.13-6.48-17.74-24.29-26.33-31.4-39.08-40.85-47.67-51.18-70.98-91.23-110.11-162.92-5.7-20.67-22.22-23.41-23.5-23.59-26.76-29.94
0-5.58-4.310-0.16-1.44-0.57-0.19000000000000000000
00000000000000000000000000
-0.02-1.851.01-9.574.654.466.536.448.528.633.140.98-0.083.2938.0126.8115.97-36.0512.480.49-0.09-1.21-0.50.792.191.04
00.140.780.120.750.631.021.051.220.130.260.192.961.181.433.351.881.070.390.380.440.540.520.530.40.39
00.060.190.36000000.821.030.840.410.510.992.633.325.61.050.560.30.20.110.110.180.26
0.020.170.10.090.190.20.280.120.120.230.240.020.291.450.392.783.30.52000.010.050.030.030.020.02
02002104010000000000000003107000000
00.030.020000000001.52001.803500000000
0.020.421.090.780.980.841.31.171.341.181.531.055.183.142.8110.568.542.191.440.941.061.490.660.670.60.67
01.641.631.63000000001.982.322.563.820.33000000000
0000000000000305000000000000
00.070.158.350.520.440.360.260.380.220.120.621.831.30.95.0631.430.940.12000000.260.16
01.711.789.980.520.440.360.260.380.220.120.623.813.653.518.8831.760.940.12000000.260.16
0.022.132.8710.761.51.281.661.431.721.41.651.678.996.796.3219.4440.2643.131.560.941.061.490.660.670.860.84
00.283.881.196.155.748.197.8710.2410.034.792.658.9110.0844.3346.2556.237.0814.041.430.970.280.161.463.051.88
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Nuo Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Nuo Therapeutics's financial health and stability.

Assets

Nuo Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Nuo Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Nuo Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Nuo Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (k)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (k)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
1998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022
0-6-33-215-4-8-6-2-5-7-3-6-3-19-20-18-5222-14-1-100-3
000000000000001,0001,000001,0001,00000000
0000000000000000000000000
0003000000001-125000000000
052814-813202401042037-34900000
0000000000000000000000000
0000000000000000000000000
00-4-2-2-2-4-4-1-2-2-3-3-4-11-11-17-14-10-40000-3
00000000000000-20000000000
00-1,000-2,00000000000-2,0000-1,0001,000000000000
000-200000000-1002000000000
0000000000000000000000000
0073325000111394-205000000
00000013310032363207200014
00733273321145131030012200014
-------------------------
0000000000000000000000000
001-1002010-1-1-110012-151-100010
0-0.7-5.02-2.88-2.92-2.73-4.77-4.15-1.66-2.16-2.56-3.26-4.31-4.31-13.48-12.15-17.9-15.09-10.93-4.9-0.87-0.92-0.05-0.12-3.77
0000000000000000000000000

Nuo Therapeutics stock margins

The Nuo Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Nuo Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Nuo Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Nuo Therapeutics's sales revenue. A higher gross margin percentage indicates that the Nuo Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Nuo Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Nuo Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Nuo Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Nuo Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Nuo Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Nuo Therapeutics Margin History

Nuo Therapeutics Gross marginNuo Therapeutics Profit marginNuo Therapeutics EBIT marginNuo Therapeutics Profit margin
202379.28 %-520.64 %-521.16 %
202281.82 %-3,018.18 %-2,881.82 %
202179.28 %0 %0 %
202079.28 %0 %0 %
201920 %-646.67 %-793.33 %
201888.32 %-109.49 %-112.41 %
2017-51.39 %-865.28 %-2,080.56 %
201626.82 %-377.73 %1,021.82 %
201530.76 %-123.98 %-458.82 %
201412.76 %-241.11 %-243.3 %
201326.97 %-156.44 %-175.02 %
201262.97 %-117.14 %-187.59 %
201162.34 %-48.55 %-53.24 %
201058.82 %-138.11 %-231.2 %
200977.78 %-166.67 %-157.97 %
200871.29 %-208.13 %-367.46 %
200756.19 %-275.77 %-261.34 %
200648.21 %-200.51 %-104.62 %
200541.45 %-483.55 %-426.97 %
200437.39 %-716.52 %-983.48 %

Nuo Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Nuo Therapeutics earnings per share therefore indicates how much revenue Nuo Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Nuo Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Nuo Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Nuo Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Nuo Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Nuo Therapeutics Revenue, EBIT and net profit per share

DateNuo Therapeutics Sales per ShareNuo Therapeutics EBIT per shareNuo Therapeutics Earnings per Share
20230.01 undefined-0.08 undefined-0.08 undefined
20220 undefined-0.08 undefined-0.08 undefined
20210 undefined-0 undefined-0.03 undefined
20200 undefined-0.01 undefined0.28 undefined
20190.01 undefined-0.04 undefined-0.05 undefined
20180.06 undefined-0.06 undefined-0.07 undefined
20170.05 undefined-0.43 undefined-1.02 undefined
20160.22 undefined-0.84 undefined2.26 undefined
20150.09 undefined-0.11 undefined-0.42 undefined
20140.06 undefined-0.16 undefined-0.16 undefined
20130.11 undefined-0.17 undefined-0.2 undefined
20120.13 undefined-0.15 undefined-0.24 undefined
20110.14 undefined-0.07 undefined-0.08 undefined
20100.1 undefined-0.14 undefined-0.23 undefined
20090.06 undefined-0.1 undefined-0.09 undefined
20080.06 undefined-0.13 undefined-0.24 undefined
20070.07 undefined-0.18 undefined-0.17 undefined
20060.07 undefined-0.14 undefined-0.07 undefined
20050.06 undefined-0.3 undefined-0.27 undefined
20040.06 undefined-0.46 undefined-0.63 undefined

Nuo Therapeutics business model

Nuo Therapeutics Inc is a US-American company specializing in the development and marketing of medical products and therapies for wound healing. The company was originally founded in 2002 as Cytomedix and was renamed Nuo Therapeutics in 2016. The company's history stems from the discovery of growth factors produced by human platelets, which play an important role in wound healing. Research has shown that these growth factors can be used to expedite wound healing, making it a promising approach for the development of new medical therapies. Nuo Therapeutics aims to develop and bring innovative wound healing products and therapies to the market. The company specializes in three main areas: biosurgery, dermatology, and advanced wound care. In the biosurgery division, Nuo Therapeutics offers a range of medical products that can be used for hemostasis and wound care. This includes Nexagon® Gel, a wound treatment product based on the aforementioned growth factors, and SurgiWrapTM, a barrier membrane for the protection of surgically treated soft tissues. In the dermatology division, Nuo Therapeutics focuses on the development of therapeutic products for the treatment of skin conditions such as eczema, psoriasis, and acne. To this end, the company has entered into an agreement with a leading pharmaceutical company to develop the skincare product SECUAADTM. The advanced wound care division of Nuo Therapeutics focuses on the treatment of difficult, chronic wounds that do not heal. In this area, the company has acquired the rights to a unique technology called AurixTM, which is based on the use of growth factors from the patient's own blood. With AurixTM, Nuo Therapeutics aims to help patients with hard-to-heal wounds heal their wounds faster and more safely. The business model of Nuo Therapeutics is based on the development and commercialization of innovative medical products and therapies. The company relies on partnerships with other companies in the pharmaceutical and medical industries to support the development and marketing of its products. Nuo Therapeutics has experienced strong growth in recent years and has established itself as a key player in the market for medical wound healing products. With its innovative products and therapies, the company is well positioned to continue growing in the future and make a significant contribution to improving medical care for patients worldwide. Nuo Therapeutics is one of the most popular companies on Eulerpool.com.

Nuo Therapeutics SWOT Analysis

Strengths

Nuo Therapeutics Inc has several competitive strengths that contribute to its success in the market. Firstly, the company has a strong research and development team, allowing it to continually innovate and develop new and effective therapies. Additionally, Nuo Therapeutics Inc has established strong partnerships with healthcare providers and institutions, providing a solid distribution network for its products. Furthermore, the company's strong financial position enables it to invest in cutting-edge technologies and expand its market presence. Finally, Nuo Therapeutics Inc has a talented and experienced workforce that is dedicated to delivering high-quality products and services.

Weaknesses

Despite its strengths, Nuo Therapeutics Inc also faces certain weaknesses that may hinder its performance. One major weakness is the company's limited product portfolio, with a focus on a specific therapeutic area. This narrow focus may limit its market reach and make it vulnerable to changes in the industry. Additionally, the company may face challenges in scaling its operations and manufacturing processes to meet increasing demand. Finally, Nuo Therapeutics Inc could benefit from enhancing its brand awareness and marketing efforts to differentiate itself from competitors.

Opportunities

Nuo Therapeutics Inc has several opportunities for growth and expansion in the market. Firstly, the increasing prevalence of its target therapeutic area presents a significant opportunity for the company to tap into a larger patient population. Furthermore, the growing demand for advanced medical technologies and therapies opens avenues for Nuo Therapeutics Inc to capture market share. Additionally, strategic partnerships with pharmaceutical companies or research institutions can help accelerate product development and market entry. Finally, expanding into international markets can provide Nuo Therapeutics Inc with access to new customers and revenue streams.

Threats

Nuo Therapeutics Inc faces various threats that may pose challenges to its business operations. Firstly, intense competition within the industry from both established companies and new entrants can impact the company's market share. Moreover, regulatory and legal complexities could create obstacles in obtaining necessary approvals and complying with industry standards. Additionally, economic downturns or changes in healthcare policies can affect the demand and affordability of Nuo Therapeutics Inc's products. Lastly, rapid technological advancements could make current therapies obsolete or less effective, requiring continuous investment in research and development.

Nuo Therapeutics Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Nuo Therapeutics Revenue by Segment

Segmente2018
License750,000 USD
Product332,437 USD
Royalty288,157 USD
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Nuo Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Nuo Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Nuo Therapeutics shares outstanding

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Nuo Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Nuo Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Nuo Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Nuo Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Nuo Therapeutics.

Nuo Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/2011-0.04 -0.03  (26.47 %)2011 Q1
12/31/2010-0.04 -0.05  (-22.55 %)2010 Q4
9/30/2010-0.03 -0.04  (-30.72 %)2010 Q3
6/30/2010-0.02 -0.05  (-145.1 %)2010 Q2
3/31/2010-0.03 -0.03  (1.96 %)2010 Q1
1

Nuo Therapeutics shareholders

%
Name
Stocks
Change
Date
24.55121 % Sheedy (Charles E)11,440,865125,0009/18/2024
11.11233 % Pittman (Scott M)5,178,345135,0005/20/2024
10.51502 % Boyalife Investment Fund I, Inc.4,900,00003/15/2024
6.00858 % Jacobs (Paul Anthony)2,800,000300,0009/30/2024
4.68490 % Deerfield Management Company, L.P.2,183,164-516,83612/31/2023
4.23897 % Jorden (David Emerson)1,975,35803/15/2024
1.26540 % Clausen (Peter A)589,67515,0005/20/2024
0.05365 % Winzer (Eric C)25,00003/15/2024
0.01009 % Ancora Advisors, L.L.C.4,70006/30/2024
1

Nuo Therapeutics Executives and Management Board

Dr. Peter Clausen

(57)
Nuo Therapeutics Chief Operating Officer, Chief Scientific Officer
Compensation 213,247

Mr. David Jorden

(60)
Nuo Therapeutics Chief Executive Officer, Chief Financial Officer, Director (since 2008)
Compensation 170,536

Mr. Scott Pittman

(64)
Nuo Therapeutics Independent Director
Compensation 1,429

Dr. Paul Mintz

(74)
Nuo Therapeutics Independent Director
Compensation 1,072

Mr. C. Eric Winzer

(66)
Nuo Therapeutics Independent Director
Compensation 1,072
1

Most common questions regarding Nuo Therapeutics

What values and corporate philosophy does Nuo Therapeutics represent?

Nuo Therapeutics Inc represents a values-driven corporate philosophy focused on advancing advanced wound care solutions. The company is committed to improving patient outcomes through innovation, research, and development. Nuo Therapeutics Inc places a strong emphasis on integrity, delivering high-quality products, and fostering collaborations with healthcare professionals. By prioritizing patient needs, the company strives to provide effective therapies that enhance healing processes. Nuo Therapeutics Inc's dedication to excellence and its patient-centered approach make it a leading player in the field of advanced wound care.

In which countries and regions is Nuo Therapeutics primarily present?

Nuo Therapeutics Inc is primarily present in the United States of America.

What significant milestones has the company Nuo Therapeutics achieved?

Nuo Therapeutics Inc has achieved significant milestones in its journey. The company successfully developed and gained FDA approval for the Aurix System, a groundbreaking autologous wound treatment technology. It has also established a robust distribution network, expanding its reach and ensuring widespread availability of its products. Nuo Therapeutics Inc has consistently demonstrated a commitment to innovation and research, making advancements in regenerative medicine. The company's strong financial performance and strategic partnerships have further solidified its position in the healthcare industry. This has enabled Nuo Therapeutics Inc to make a positive impact on patient care and position itself as a leading player in the field.

What is the history and background of the company Nuo Therapeutics?

Nuo Therapeutics Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative products for the treatment of chronic wound care. Founded in 2009, Nuo Therapeutics specializes in biodefense, regenerative medicine, and bioelectric medicine. The company focuses on utilizing its patented platform technology, Aurix, to provide advanced wound care solutions. Nuo Therapeutics aims to enhance the healing process and improve patient outcomes through the application of bioelectric stimulation. With a strong commitment to research and development, Nuo Therapeutics continues to make advancements in the field of wound care, ensuring optimal treatment options for patients worldwide.

Who are the main competitors of Nuo Therapeutics in the market?

The main competitors of Nuo Therapeutics Inc in the market include companies such as Acelity, Smith & Nephew, and Molnlycke Health Care.

In which industries is Nuo Therapeutics primarily active?

Nuo Therapeutics Inc is primarily active in the healthcare and biotechnology industries.

What is the business model of Nuo Therapeutics?

Nuo Therapeutics Inc is a biomedical company that focuses on developing and commercializing innovative products for the management of chronic wounds. Their business model revolves around providing advanced therapies for patients with chronic ulcers, such as their flagship product Aurix. Nuo Therapeutics Inc aims to improve healthcare outcomes by offering autologous therapies that utilize a patient's own platelet and plasma components. With a focus on regenerative medicine, Nuo Therapeutics Inc strives to address the unmet needs of patients suffering from non-healing wounds, offering novel treatment options that can potentially accelerate the healing process.

What is the P/E ratio of Nuo Therapeutics 2025?

The P/E ratio cannot be calculated for Nuo Therapeutics at the moment.

What is the P/S ratio of Nuo Therapeutics 2025?

The P/S cannot be calculated for Nuo Therapeutics currently.

What is the Quality Investing of Nuo Therapeutics?

The Quality Investing for Nuo Therapeutics is 3/10.

What is the revenue of Nuo Therapeutics 2025?

The revenue cannot currently be calculated for Nuo Therapeutics.

How high is the profit of Nuo Therapeutics 2025?

The profit cannot currently be calculated for Nuo Therapeutics.

What is the business model of Nuo Therapeutics

Nuo Therapeutics Inc is a pharmaceutical company focused on the development and marketing of novel biological products for patients suffering from various chronic wounds, such as diabetic foot ulcers. The company has two divisions: the wound care division and the neurological regeneration division. The wound care division offers the unique Autologous Wound Matrix (AWM®) System, which is made from the patient's own blood. The AWM® System promotes healing of chronic wounds in patients by forming a matrix that supports the growth of new cells and tissues. This system is used in patients with chronic wounds who do not respond to other treatment methods or have delayed wound healing. The neurological regeneration division offers the Neuropathological Sibling System (NGS®), which is designed to restore the cognitive abilities of stroke patients. The NGS® System supports patient rehabilitation through the use of innovative medical devices specifically developed to increase blood circulation and stimulate the brain. Nuo Therapeutics aims to revolutionize the care of patients with chronic wounds and stroke patients by offering industry-leading biological products and advanced technologies. Nuo Therapeutics' business model is based on an innovative approach, working closely with physicians, hospitals, and insurance companies to optimize patient care. The company focuses on marketing products based on sound research and development that have been approved by the US Food and Drug Administration (FDA). Nuo Therapeutics relies on a highly qualified team of scientists, engineers, and physicians actively involved in the research and development of new products and technologies. These teams collaborate closely with renowned universities, research institutions, and hospitals to optimize the effectiveness and safety of their products. Nuo Therapeutics is working on expanding its business through the development of new therapies to improve outcomes for patients with chronic wounds and stroke patients. The company also plans to expand its presence internationally to enhance access to its products in international markets. Overall, Nuo Therapeutics is a leading company in wound care and neuroregeneration. The company is committed to providing its patients with high-quality treatment options by introducing innovative products and technologies to the market. With a dedicated team of innovative thinkers and researchers, Nuo Therapeutics will continue to revolutionize the care of patients with chronic wounds and stroke patients in the future.

What is the Nuo Therapeutics dividend?

Nuo Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Nuo Therapeutics pay dividends?

The dividend cannot currently be calculated for Nuo Therapeutics or the company does not pay out a dividend.

What is the Nuo Therapeutics ISIN?

The ISIN of Nuo Therapeutics is US67059V2097.

What is the Nuo Therapeutics WKN?

The WKN of Nuo Therapeutics is A2AP5P.

What is the Nuo Therapeutics ticker?

The ticker of Nuo Therapeutics is AURX.

How much dividend does Nuo Therapeutics pay?

Over the past 12 months, Nuo Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Nuo Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Nuo Therapeutics?

The current dividend yield of Nuo Therapeutics is .

When does Nuo Therapeutics pay dividends?

Nuo Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Nuo Therapeutics?

Nuo Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Nuo Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Nuo Therapeutics located?

Nuo Therapeutics is assigned to the '-' sector.

Wann musste ich die Aktien von Nuo Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Nuo Therapeutics from 3/3/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 3/3/2025.

When did Nuo Therapeutics pay the last dividend?

The last dividend was paid out on 3/3/2025.

What was the dividend of Nuo Therapeutics in the year 2024?

In the year 2024, Nuo Therapeutics distributed 0 USD as dividends.

In which currency does Nuo Therapeutics pay out the dividend?

The dividends of Nuo Therapeutics are distributed in USD.

All fundamentals about Nuo Therapeutics

Our stock analysis for Nuo Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nuo Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.